Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156779 | 0.81 | DPP7 (0.41) | DPP8DPP9DPP7DPP4 | |
| SCHEMBL25099321 | 0.80 | DPP7 (0.40) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL7990837 | 0.78 | CYP3A4 (0.43) | CYP3A4MAPK1 | |
| SCHEMBL14268998 | 0.77 | TAS1R3 (0.40) | CYP3A4MAPK1 | |
| SCHEMBL9716630 | 0.75 | FOLH1 (0.58) | NMT2NMT1GSRSIRT6SIRT1 | |
| SCHEMBL14961163 | 0.75 | SIRT6 (0.43) | NMT2NMT1DPP8DPP9DPP7 | |
| SCHEMBL9716627 | 0.75 | FOLH1 (0.58) | NMT2NMT1GSRSIRT6SIRT1 | |
| SCHEMBL14961162 | 0.75 | SIRT6 (0.43) | NMT2NMT1DPP8DPP9DPP7 | |
| SCHEMBL26842419 | 0.74 | NMT1 (0.42) | NMT2NMT1GSRRNPEPFOLH1 | |
| SCHEMBL3126966 | 0.73 | ITGB3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-8410300-B2 | Protease inhibitors | TAIMED BIOLOGICS, INC. (TW) | 2013-04-02 | — | — | US | disclosed |
| EP-2258680-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | TAIMED BIOLOG INC (TW) | 2012-09-19 | — | — | EP | disclosed |
| EP-2258680-A2 | Aromatic derivatives as HIV aspartyl protease inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258681-A2 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-20100184974-A1 | Protease Inhibitors | AMBRILIA BIOPHARMA INC. (CA) | 2010-07-22 | — | — | US | disclosed |
| EP-2064177-A2 | PROTEASE INHIBITORS | Ambrilia Biopharma Inc. (CA) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008078200-A2 | PROTEASE INHIBITORS | AMBRILIA BIOPHARMA INC. (CA) | 2008-07-03 | — | — | WO | disclosed |
| EP-1575914-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056764-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2004-07-08 | — | — | WO | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184974-A1 | Protease Inhibitors | PREP, CTRL, CTRB1 | NMT2 2702/4885NMT1 2612/4885DPP8 48/4885 |
| US-20130158261-A1 | PROTEASE INHIBITORS | PREP, CTRL, CTRB1 | NMT2 2702/4885NMT1 2612/4885DPP8 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.